clene-logo@2x.png
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
November 28, 2022 08:00 ET | Clene Inc.
CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct...
clene-logo@2x.png
Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
November 07, 2022 08:00 ET | Clene Inc.
Secondary survival endpoint for the CNM-Au8® 30 mg dose investigated in the Healey ALS Platform Trial demonstrated a >90% reduction in the risk of death or death equivalent (permanently assisted...
clene-logo@2x.png
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
October 31, 2022 08:00 ET | Clene Inc.
SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
clene-logo@2x.png
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
October 03, 2022 08:00 ET | Clene Inc.
The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeksPrespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose...
clene-logo@2x.png
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
September 30, 2022 16:12 ET | Clene Inc.
SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
clene-logo@2x.png
Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference
September 21, 2022 07:00 ET | Clene Inc.
Treatment with CNM-Au8 significantly improved long-term survival with approximately a 70% decreased risk of mortality vs. original placebo randomizationComparable survival benefits were also shown...
clene-logo@2x.png
Clene to Present at Upcoming September Investor Conferences
August 30, 2022 07:00 ET | Clene Inc.
SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
clene-logo@2x.png
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
August 15, 2022 07:00 ET | Clene Inc.
CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT...
clene-logo@2x.png
Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights
August 15, 2022 07:00 ET | Clene Inc.
Topline results from the Phase 2 VISIONARY-MS clinical trial with CNM-Au8® met the primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional...
clene-logo@2x.png
Clene to Host VISIONARY-MS Results Call and Webcast on August 15
August 12, 2022 16:01 ET | Clene Inc.
SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...